Xcounter Share Discussion Threads

[troutisout] 01/12/2011 13:02

Updated info on the PEER thread, with M&A activity happening it's worthwhile watching some of these Medical small caps

[troutisout] 08/7/2011 07:46

troutisout - 7 Jul'11 - 15:06 - 15 of 21 edit


Right I have gone back over ADVFN's info and have come up with this,

LID EV/Sales 28.18/6.24......4.52
DEMG EV/Sale 35.41/6.28......5.64
ASD EV/Sales 259.84/101.68...2.56 - PE 45
ODX EV/Sales 13.5/7.9........1.71 - PE 155
MDW EV/Sales 3.06/10.48......0.29 - PE 14.08
AOR EV/Sales 4/1.36..........2.94
LMT EV/Sales 30.48/3.01.....10.13
XCT EV/Sales 8.13/3.1........2.62
TSTL EV/Sale 14.25/8.76......1.63 - PE 12
SUN EV/Sales 39/7.05.........5.53 - PE 21.61


Well from the table above we can see some wild differences in each valuation factor.
Using ASD as an example (as we know what a comnpetitor was prepared to offer) it doesn't seem to have been the PE ratio that it was worked from, the Ev/sales figure of 2.56 looks to be in the centre of the range.

so are EV/Sales the best way to look at value, certainly with so many not actually in profit PE and PEG are out the window.

I would like to look more into forecast PEs but will need to see broker forecasts if there are any on some of the above shares, if anyone can post a link to any forecasts for any of the above, it will be greatly appreciated.


Come and add any facts you can on these and any other smallcap medical equipment companies,

[troutisout] 07/7/2011 09:52

I have started a thread to try and compare the AIM/small cap medical equipment manufacturers as a peer group, hopefully to get some sort of handle on how and why the market assigns certain valuations to each Company and what is the peer group average and whether that will rise as M&A activity and a renewed interest in biotech and small pharma shares spills over to the medical equipment side. Please feel free to add any facts you think affect the valuation or any other comparable companies I have missed out.

[fineart333] 27/4/2011 07:35

RNS Number : 5173F

XCounter AB

27 April 2011

PRESS RELEASE Stockholm, 27 April 2010 Result of Annual General Meeting and Board Update

XCounter AB (AIM: XCT) ("XCounter"), a technology leader in the development of photon counting X-ray detectors and tomosynthesis based 3D medical imaging, held its Annual General Meeting yesterday in Stockholm. The resolutions to amend the Company's articles of association, the resolution to carry out a share consolidation, the resolution to approve the Company's de-listing and the resolution to authorise the board to issue shares were not passed by shareholders, as they did not achieve the requisite majority of two thirds of votes cast in favour. The resolution re-electing the members of the board was duly passed by shareholders, however, Yngvar Hansen-Tangen chose not to be re-elected and resigns from the Board with immediate effect. All other resolutions proposed were duly passed by the shareholders. Consequently, the Company will not presently proceed with the proposed de-listing from AIM, the listing on the NASDAQ OMX First North market in Stockholm and the share consolidation. Additionally, a group of minority shareholders requested a special investigation pursuant to chapter 10 section 21 of the Swedish Companies Act to look into certain defined aspects of the company's operations. The request gives shareholders the right to require the appointment of a person by the Swedish authorities (Lansstyrelsen) to investigate such aspects. The Company will make further announcements as necessary. For further information, please contact: XCounter AB Tel: [phone] Mikael Strindlund, CEO Nomura Code Securities Tel: [phone] Phil Walker Capital MS&L Tel: [phone] Mary Clark/Anna Davies About XCounter AB XCounter AB is a leader in the development of photon counting detector and tomosynthesis-based 3D medical imaging technology. For more information, please visit: www.xcounter.se

This information is provided by RNS

The company news service from the London Stock Exchange

END

[barrywhit] 18/1/2011 10:36

RNS Number : 6495Z

XCounter AB

18 January 2011

18 January 2011

XCounter AB (publ)

Result of EGM

XCounter AB (publ) (AIM:XCT), a technology leader in direct conversion and photon counting for medical, dental and industrial digital X-ray imaging, is pleased to announce that the resolutions to approve the Placing and to appoint Yngvar Hansen-Tangen as a Non-Executive Director of XCounter were duly passed by Shareholders at the EGM earlier today.

Placing of 77,470,412 Shares Subject to the Placing Shares being registered by the Swedish Companies Registration Office on 21 January 2011, it is expected that the Placing Shares will be admitted to trading on AIM on 25 January 2011. The net proceeds (approximately GBP1.815 million) will provide funding for the Group's organic growth strategy and business.

Lothar Koob, Chairman of XCounter, commented: "We made considerable progress last year in establishing our position as a leader of direct conversion as well as cutting edge X-ray detectors. This placing provides XCounter with the resources to build on this success in 2011. Detectors using XCounter's digital direct conversion solid state detector and photon counting technologies enable superior image quality at minimal radiation dose across a wide spectrum of applications in medical, dental and industrial imaging."

Further details of the Placing are set out in the circular posted to Shareholders on 23 December 2010 (the "Circular"), a copy of which is available on the Company's website (www.xcounter.se). Defined terms used in this announcement shall have the same meaning as set out in the Circular.

New Board member In addition, following the EGM with immediate effect Yngvar Hansen-Tangen has joined the Board of XCounter as a Non-Executive Director. Hansen-Tangen is a part time medical doctor and is a director of and significant shareholder in Viking Holding AS, a company which holds 2.31% of the issued share capital of XCounter.

Welcoming Hansen-Tangen to the Board, Lothar Koob said: "Yngvar Hansen-Tangen's appointment will bring valuable industrial experience to the Board at an exciting point in XCounter's development and I am delighted to welcome him to his new role."

- Ends -

[fineart333] 12/5/2010 07:30

RNS Number : 7611L
XCounter AB
12 May 2010

?
XCounter


PRESS RELEASE

Stockholm, 12 May 2010


XCounter AB and Artemis Imaging GmbH sign agreement to develop innovative 3-D
breast imaging system

XCounter AB (AIM: XCT) ("XCounter"), a technology leader in the development of
photon counting X-ray detectors and tomosynthesis-based 3D medical imaging, and
Artemis Imaging GmbH ("Artemis"), have today signed a conditional agreement (the
"Agreement") for the development and delivery of an innovative 3-D mammography
CT system. The new breast imaging system will incorporate XCounter's innovative
digital photon counting solid state detector platform, which enables fast, high
quality 3-D imaging with the lowest possible radiation dose.

Artemis aims to develop, validate and perform clinical evaluation ofa dedicated
low-dose 3-D X-ray computed tomography (CT) scanner for the female breast. The
breast CT system shall provide very high 3D spatial resolution of about 100 µm,
yet work at dose levels comparable to today's standard, bi-plane digital
mammography. As superposition-free CT imaging is provided, performance is
expected to exceed that of mammography significantly with respect to sensitivity
and specificity.

According to the Agreement, Artemis will fund XCounter's Mammo CT detector
development costs including a first delivery of a fully functioning prototype to
secure exclusivity for the detector system. The Agreement is conditional upon
Artemis finalizing full funding of the project. A significant portion of the
funding is already secured.

Professor Willi Kalender, CEO of Artemis Imaging GmbH, said:
"XCounter has proven that its solid state photon counting detector technology
fulfils all the requirements for Artemis' revolutionary, dedicated breast CT
system which combines superb image quality with lowest possible radiation dose,
which are crucial for this application. The performance characteristics of the
technology will surpass all other existing approacheson the market. I am
confident that we can secure the remaining balance of the financing required for
this project and I look forward to working with XCounter on this development."

Mikael Strindlund, CEO of XCounter, said:
"This is a true breakthrough for patients and for XCounter. The cutting edge
technologies from AJAT and XCounter offers state of the art solid detector and
photon counting enabling fast, high quality 3-D imaging with lowest possible
radiation dose. This agreement confirms our leading position in photon counting
detection technology. We are looking forward to developing this project, and
other potential imaging projects with Artemis."


This agreement follows on from a collaboration announced in 2009, in which
Artemis reviewed the potential for the XCounter technology in developing a new
detector. The agreement is further validation of the potential medical
applications of XCounter's technology.



For further information, please contact:

XCounter AB Tel: [phone]
Mikael Strindlund, CEO

Nomura Code Securities Tel: [phone]
Phil Walker/Clare Terlouw

Capital MS&L Tel: [phone]
Mary Clark/Anna Davies

This information is provided by RNS
The company news service from the London Stock Exchange
END

AGRKMGMKKZZGGZG

[futureearner] 16/4/2010 07:40

Sent three emails to their IR, no replies....very poor. Fancied another top up here, but not as yet until I get a reply!?!

[srebmit] 09/4/2010 11:11

What's happening with this one Buystock? You have been ramping this for months, but the only movements are down. Any chance of some real action with this, or is it just wishful thinking on your part?

[buystock] 18/3/2010 04:35

ALSO now overdue and possible 25th update.XCounter Announces Positive Results Following Independent Clinical Evaluation Of XC Mammo -3T Prototype XCounter AB (publ) (AIM:XCT), a technology leader in the development of tomosynthesis-based 3D medical imaging, announced positive initial results from the first clinical evaluation of its innovative breast screening device XC Mammo - 3T. The device is the world's first dedicated 3D digital mammography system for the detection of breast cancer, the most common form of cancer found in women .Mikael Strindlund, CEO of XCounter said:
"The positive results of our first prototype installation in a clinical environment is a major achievement for XCounter. I am particularly encouraged to hear that, unlike other imaging systems, XC Mammo - 3T can confidently detect micro-calcifications, helping to identify abnormalities earlier in their development."

The findings from the independent clinical evaluation will be developed into a comprehensive clinical report during 2009.

[buystock] 18/3/2010 04:03

Palpable breast cancers are more common in women not undergoing annual mammography.CHICAGO (March 15, 2010) -- New research findings published in the March issue of the Journal of the American College of Surgeons indicate that some breast cancers continue to be detected as a palpable lump rather than being found through mammographic screening. Patients who presented with palpable tumors -- those detected as a result of breast complaint or during examination -- had larger tumors and were at a more advanced stage at diagnosis. The women who underwent yearly mammographic screening had the lowest rate of palpable presentation, in keeping with the reported benefit of mammography for early detection. Additionally, the data suggested that clinical breast examination (CBE) and breast self-examination should continue to play a role in detecting breast cancer
MRI: Non-invasive diagnostic tool for diagnosing testicular cancer
February 22, 2010 Researchers have found that non-invasive magnetic resonance imaging (MRI) is a good diagnostic tool for the evaluation and staging of testicular cancer and may improve patient care by sparing some men unnecessary surgery, according to a study in the March issue of the American Journal of Roentgenology.

[buystock] 18/3/2010 02:58

dubois e-mailed you.

[buystock] 17/3/2010 16:42

dubois i have over 500k of these this is my favourite stock by a country mile.average 6.7p.it has all the makings of a major player but is way overlooked.3dt mammo scan partnership with artemis should come on the 25th along with a 2.8m grant artemis applied for from the german government.fully funded pr-xmas and instutions loading up.no 1 trick pony go to AJAT OY OUR FINNISH COMPANY.JUST PUT A NEW PRODUCT ON THE MKT FOR dental use.£24k a hit plus maintainance they are going of the production line like hotcakes + ndt radiography for pipe welds in norwegian sector.thats enough for now .THE NEW /ajat art cdt sensor now on sale through f1fimet. IntraOS 70 - intra-oral x-ray unit for traditional and digital pictures; wall mounted, 70kV, short/medium/long arm page 1Subsidiary signs major development agreement
page 2 £1,850.00
IntraOS 70 - intra-oral x-ray unit for traditional and digital pictures; mobile, 70kV page 1
page 2 £1,950.00
IntraOS 70 DG - intra-oral x-ray unit designed specifically for digital images - 0.4 focal spot; wall mounted brochure £TBA
extra-oral OPG (traditional)
PantOS 16 Xp - traditional OPG brochure £10,490.00
PantOS 16 Xp Ceph - traditional OPG with cephalometric arm £12,990.00
extra-oral OPG (digital)
PantOS Dg Xp - digital OPG brochure £16,990.00
NEW PantOS Dg Xp Ceph - digital OPG with cephalometric arm, product launched at the International Dental Show 2009 in Cologne, unbeatable price for a digital, panoramic x-ray unit with cephalometric arm, image size: panoramic 3580 x 1535 pix, ceph 5300 x 4608 pix brochure £24,990.00
25th draws close.WHITEHORSE CAPITAL TOOK 11% IN DEC 2009 .and probable grant news due on the 26th january a bonus as we are now fully funded.wait for the A.A BUY.Co-development of the breast CT scanner provides a cost effective way for XCounter to progress the
development of the detector technology as, under the current proposals, Artemis intends to provide €1.75m
over a period of two years during the R&D phase of the project. Artemis would fund XCounter's detector
development in return for exclusivity for the PCT technology in the Mammo CT application.
Artemis has applied for a €2.8m grant from the German government (Bundesministerium für Bildung und
Forschung) to fund half of the project. It is currently anticipated that the German government will announce
the results of the grant application on or around 26 January 2010.
If Artemis' application for the grant is successful, the Company anticipates negotiating and signing a co-
development agreement with Artemis in the first quarter of 2010 which will include provisions granting
Artemis exclusivity for the PCT technology for the Mammo CT application. Following the developmental
phase, Artemis proposes to licence the product to a major OEM and it is XCounter's current intention at that
time to enter into a supply agreement with Artemis, so as to exclusively manufacture and supply the detector
components to be integrated into the completed Mammo CT device.
The Directors believe that the total initial market for the complete Mammo
CT systems to be €150m per annum. 21
Posts: 804 margic21

Answer
Opinion: Strong Buy
Price: 6.00
artemis..4 Mar '10

was on the phone to a member of staff today... been in contact via email... they say there application has taken longer as it has been viewed as a business loan as opposed to a grant... however, although they will not release and price sensitive information they did comment... ' Mr ioannou (me).. we believe we will get the result we had expected before considering any form of application, and will be informing all relevant associates of our plans once we have received official conformation.. we expect to be working closer to the mention company (xct) within 2 weeks and possible much sooner.' i could only buy 25 thousand shares and as you can see they have yet to appear on any market.. but are in my account and im now very excited.. i soon expect to see a news release or two followed by a re-rating within 3 months... for me this is a huge multi-bagger and i dont often set a recommendation on a stock.. but i cannot believe this is falling under the radar... but happy to be invested and see 30p a easy target short term.... people will be missing this one

[buystock] 17/3/2010 10:24

should be but off the radar at present should spring too life news on the 25th roughly

[whe4to] 17/3/2010 10:23

Looks like a market cap of £5.5m, with £2m in cash, a possible jv and a government grant!

Could be a very busy few weeks here...

[buystock] 17/3/2010 04:55

25th draws close.WHITEHORSE CAPITAL TOOK 11% IN DEC 2009 .and probable grant news due on the 26th january a bonus as we are now fully funded.wait for the A.A BUY.Co-development of the breast CT scanner provides a cost effective way for XCounter to progress the
development of the detector technology as, under the current proposals, Artemis intends to provide €1.75m
over a period of two years during the R&D phase of the project. Artemis would fund XCounter's detector
development in return for exclusivity for the PCT technology in the Mammo CT application.
Artemis has applied for a €2.8m grant from the German government (Bundesministerium für Bildung und
Forschung) to fund half of the project. It is currently anticipated that the German government will announce
the results of the grant application on or around 26 January 2010.
If Artemis' application for the grant is successful, the Company anticipates negotiating and signing a co-
development agreement with Artemis in the first quarter of 2010 which will include provisions granting
Artemis exclusivity for the PCT technology for the Mammo CT application. Following the developmental
phase, Artemis proposes to licence the product to a major OEM and it is XCounter's current intention at that
time to enter into a supply agreement with Artemis, so as to exclusively manufacture and supply the detector
components to be integrated into the completed Mammo CT device.
The Directors believe that the total initial market for the complete Mammo
CT systems to be €150m per annum.

[buystock] 16/3/2010 16:40

jonno you will have regrets here from this level ive done my stuff on this one instutions have loaded up since last year and the reward will come this month.

[buystock] 16/3/2010 07:56

tick-tock getting exciting and still no volume YET.

[buystock] 15/3/2010 07:34

jonno this wont be single digits after the interims roughly the 25th

[jonno1] 15/3/2010 07:23

what...from 5.5 - 7.0 to 6.0 - 7.5 ?

[buystock] 15/3/2010 04:05

pendulam ready too swing

[buystock] 14/3/2010 09:44

getting close too news now i feel.